IL15

Summary

IL15 (interleukin 15, HGNC:5977) is a protein-coding gene on chromosome 4q31.21, encoding Interleukin-15 (P40933). Cytokine that plays a major role in the development of inflammatory and protective immune responses to microbial invaders and parasites by modulating immune cells of both the innate and adaptive immune systems.

The protein encoded by this gene is a cytokine that regulates T and natural killer cell activation and proliferation. This cytokine and interleukine 2 share many biological activities. They are found to bind common hematopoietin receptor subunits, and may compete for the same receptor, and thus negatively regulate each other’s activity. The number of CD8+ memory cells is shown to be controlled by a balance between this cytokine and IL2. This cytokine induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6. Studies of the mouse counterpart suggested that this cytokine may increase the expression of apoptosis inhibitor BCL2L1/BCL-x(L), possibly through the transcription activation activity of STAT6, and thus prevent apoptosis. Alternatively spliced transcript variants of this gene have been reported.

Source: NCBI Gene 3600 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 27 total
• Druggable target: yes
• MANE Select transcript: NM_000585

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5977
Approved symbol	IL15
Name	interleukin 15
Location	4q31.21
Locus type	gene with protein product
Status	Approved
Aliases	IL-15, MGC9721
Ensembl gene	ENSG00000164136
Ensembl biotype	protein_coding
OMIM	600554
Entrez	3600

Gene structure

Transcript identifiers

Ensembl transcripts: 49 — 47 protein_coding, 2 retained_intron

ENST00000296545, ENST00000320650, ENST00000394159, ENST00000477265, ENST00000505351, ENST00000509249, ENST00000514653, ENST00000529613, ENST00000887020, ENST00000887021, ENST00000887022, ENST00000887023, ENST00000887024, ENST00000887025, ENST00000887026, ENST00000887027, ENST00000887028, ENST00000887029, ENST00000887030, ENST00000887031, ENST00000887032, ENST00000887033, ENST00000887034, ENST00000887035, ENST00000887036, ENST00000887037, ENST00000887038, ENST00000887039, ENST00000887040, ENST00000887041, ENST00000887042, ENST00000887043, ENST00000887044, ENST00000887045, ENST00000887046, ENST00000887047, ENST00000887048, ENST00000887049, ENST00000887050, ENST00000887051, ENST00000914397, ENST00000914398, ENST00000914399, ENST00000914400, ENST00000968087, ENST00000968088, ENST00000968089, ENST00000968090, ENST00000968091

RefSeq mRNA: 2 — MANE Select: NM_000585 NM_000585, NM_172175

CCDS: CCDS3755, CCDS3756

Canonical transcript exons

ENST00000320650 — 8 exons

Exon	Start	End
ENSE00001081765	141729847	141729984
ENSE00001081768	141721924	141722008
ENSE00001191128	141656186	141656307
ENSE00001342283	141719366	141719476
ENSE00001517654	141636583	141636748
ENSE00001959031	141732738	141733987
ENSE00003621285	141720469	141720566
ENSE00003655836	141727940	141727984

Expression profiles

Bgee: expression breadth ubiquitous, 233 present calls, max score 95.02.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.6728 / max 110.2550, expressed in 957 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
49818	1.9532	461
49817	1.0717	564
49820	0.8761	294
49822	0.3923	150
49819	0.2631	146
49821	0.1163	50

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
decidua	UBERON:0002450	95.02	gold quality
monocyte	CL:0000576	90.42	gold quality
mononuclear cell	CL:0000842	90.33	gold quality
leukocyte	CL:0000738	89.71	gold quality
stromal cell of endometrium	CL:0002255	87.26	gold quality
left lobe of thyroid gland	UBERON:0001120	86.87	gold quality
thyroid gland	UBERON:0002046	86.22	gold quality
granulocyte	CL:0000094	86.13	gold quality
right lobe of thyroid gland	UBERON:0001119	85.72	gold quality
spleen	UBERON:0002106	84.73	gold quality
descending thoracic aorta	UBERON:0002345	82.64	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.35	gold quality
mucosa of stomach	UBERON:0001199	81.81	gold quality
thoracic aorta	UBERON:0001515	81.55	gold quality
ascending aorta	UBERON:0001496	81.50	gold quality
right coronary artery	UBERON:0001625	81.01	gold quality
hindlimb stylopod muscle	UBERON:0004252	80.91	gold quality
muscle layer of sigmoid colon	UBERON:0035805	80.46	gold quality
small intestine	UBERON:0002108	80.30	gold quality
jejunal mucosa	UBERON:0000399	80.01	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.00	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.85	gold quality
endometrium	UBERON:0001295	79.52	gold quality
left coronary artery	UBERON:0001626	79.43	gold quality
germinal epithelium of ovary	UBERON:0001304	79.20	gold quality
omental fat pad	UBERON:0010414	79.09	gold quality
peritoneum	UBERON:0002358	78.98	gold quality
gastrocnemius	UBERON:0001388	78.68	gold quality
muscle of leg	UBERON:0001383	78.62	gold quality
right lung	UBERON:0002167	78.61	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	120.47
E-ANND-3	yes	4.01

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, CEBPB, DDIT3, EGR1, HMGA1, HOXA10, IRF1, IRF3, IRF4, IRF6, MYB, NFKB1, NFKB, REL, RELA, TBX21, TOX2, TP53

miRNA regulators (miRDB)

61 targeting IL15, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-95-5P	99.89	72.17	3973

Literature-anchored findings (GeneRIF, showing 40)

• role in cytokine production by antigen-presenting cells (PMID:11702064)
• Decreased IL-15 may contribute to elevated IgE and acute inflammation in atopic dermatitis (PMID:11751999)
• role of IL-15 in the regulatory function of PMN associated with IL-1beta-mediated reactions in normal conditions and, to a lesser extent, in a tumour-bearing host. (PMID:11814312)
• Endogenous IL-15 plays a role in the suppression of TH2-type cytokines in acute visceral leishmaniasis patients. (PMID:11876762)
• Interleukin-15 inhibits spontaneous apoptosis in human eosinophils via autocrine production of granulocyte macrophage-colony stimulating factor and nuclear factor-kappaB activation. (PMID:11919076)
• IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. (PMID:11972069)
• mRNA for IL-15 isoforms was constitutively expressed in all tested human fetal brain structures, indicating a role in their development and physiology. (PMID:12114302)
• il15 induce anti-tumor immune response (PMID:12115611)
• increased production of IL-15 in muscle cells in polymyositis and dermatomyositis (PMID:12147628)
• Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. (PMID:12165497)
• These results suggest that IL-15 is a potent regulator of iNOS expression by HGEC and involved in innate immunity in the mucosal epithelium. (PMID:12237122)
• role of CD28 and IL-12/IL-15 signaling impairment in T cell proliferative deficiency during senescence (PMID:12297341)
• Administration of exogenous IL-15 for 1 wk significantly augmented the expansion of the primary responding CD8+ T cell population in a murine vaccine model. (PMID:12391205)
• enhances survival, proliferation, and function of HIV-specific CD8+ T cells (PMID:12393488)
• IL-15 has been shown to regulate the homeostasis of both innate and adaptive immune cells [review] (PMID:12401478)
• IL-15 is required for expression of granulysin-mediated anticryptococcal activity in CD8 T cells. (PMID:12421959)
• Human and mouse IL-15 bound hu or mu IL-15Ralpha with equal high affinity in the presence or absence of IL-2Rbetagamma c and exhibited similar proliferative activities on cells containing all three subunits (PMID:12453470)
• Peritoneal fluid IL-15 levels are increased in women with endometriosis. IL-15 levels are inversely correlated with depth of invasion and disease stage. Possible role in early pathogenesis of endometriosis. (PMID:12571184)
• IL-15 maintains the homeostasis of peripheral V alpha 14(+) NK-T cells (PMID:12598649)
• Hematopoietic CD34+ cells secreted IL-15 that, through autocrine/paracrine loop distinct signal pathways, activated NF-kB in bone marrow and cord blood progenitors, and activated STAT3 and STAT5 in peripheral G-CSF-mobilized and BM progenitors only. (PMID:12623850)
• IL-15 has multiple effects on CD8 T cells and possesses the potential to regulate the life span of naive as well as memory CD8+ T cells in vitro. (PMID:12734346)
• may play a role in the pathogenesis of cyclosporin A-induced gingival overgrowth due to its interactions with cyclosporin A and its role in apoptosis and inflammation (PMID:12747456)
• decreased production of IL-15 occurs despite a comparable increase in IL-15 mRNA in the PBMC of HIV-infected and healthy HIV-seronegative donors when exposed to HSV-1 in cultured cells (PMID:12757260)
• Synergistic interactions between IL-15, IL-21, and IL-18 play an important role in NK and T cell functions by enhancing IFN-gamma gene expression; IL-15 efficiently stimulates STAT5 DNA binding to IFN-gamma promoter and first intron activated (GAS) site. (PMID:12759422)
• all human CD8+ T-cell subsets had the ability to respond to IL-15, which suggests a generic influence of this cytokine on CD8+ T-cell homeostasis in man. (PMID:12805064)
• The mixed leukcyte culture model suggest that allorecognition upregulates IL-2 but not IL-15 expression. (PMID:12826231)
• IL-15 up-regulates the expression of lymphocyte function-associated antigen-1 (LFA-1) in IL-7-differentiated cells and augments their cytotoxic activity. (PMID:12847234)
• IL-15 alone, similarly to IL-18, has no significant ability for regulation of both soluble IL-6 receptors, sIL-6R and sgp130, released by human neutrophils. (PMID:12857602)
• role in liver allograft rejection (PMID:12865812)
• CD34-CD133-CD7-CD45(dim)lin- hematopoietic stem cells from human umbilical cord blood display an exquisite sensitivity to IL-15 in vitro and differentiate into lymphoid/natural killer cells. (PMID:12960322)
• Interleukin-15 has a role in increasing myosin accretion in human skeletal myogenic cultures (PMID:14499665)
• IL-15 produced by metastatic colon carcinoma cells can induce hyperplasia in the mucosa adjacent to colon cancer, thus contributing to angiogenesis and progression of the disease (PMID:14581351)
• Because IL-15 regulates gene expression through the interactions of transcription factors with IFN-gamma activated sequence and Ets binding site motifs, it is likely that IL-15 influences CD94 gene expression through formation of DNA-protein complexes. (PMID:14607929)
• IL-15 stimulates type I interferon (IFN)-mediated dendritic cell (DC) expression of MICA/B and subsequent DC activation of natural killer cells. (PMID:14607946)
• results obtained with an IL-15-specific mAb support an important role for IL-15 in the pathogenesis of psoriasis (PMID:14617758)
• The anti-apoptotic effects of IL-15 may explain the rediction pf diabetes incidence in NOD mice. (PMID:14648805)
• IL-15-expanded, de novo-induced human anergic regulatory CD4+ T cells suppress both naive and memory T cells in a superior way and are of interest in antigen-specific immunotherapy. (PMID:14662842)
• HIV antiviral response is mediated primarily by production of interleukin-15 by mature dendritic cells. (PMID:14684414)
• IL-15 can improve the in vivo antitumor activity of adoptively transferred CD8(+) T cells (PMID:14762166)
• IL-15 secreted by activated alveolar macrophages and granzyme B secreted by activated CD8+ cytotoxic T lymphocytes play important roles in the process of acute lung allograft rejection (PMID:14967307)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	il15l	ENSDARG00000007743
danio_rerio	il15	ENSDARG00000052361
mus_musculus	Il15	ENSMUSG00000031712
rattus_norvegicus	Il15	ENSRNOG00000003439

Protein

Protein identifiers

Interleukin-15 — P40933 (reviewed: P40933)

All UniProt accessions (1): P40933

UniProt curated annotations — full annotation on UniProt →

Function. Cytokine that plays a major role in the development of inflammatory and protective immune responses to microbial invaders and parasites by modulating immune cells of both the innate and adaptive immune systems. Stimulates the proliferation of natural killer cells, T-cells and B-cells and promotes the secretion of several cytokines. In monocytes, induces the production of IL8 and monocyte chemotactic protein 1/CCL2, two chemokines that attract neutrophils and monocytes respectively to sites of infection. Unlike most cytokines, which are secreted in soluble form, IL15 is expressed in association with its high affinity IL15RA on the surface of IL15-producing cells and delivers signals to target cells that express IL2RB and IL2RG receptor subunits. Binding to its receptor triggers the phosphorylation of JAK1 and JAK3 and the recruitment and subsequent phosphorylation of signal transducer and activator of transcription-3/STAT3 and STAT5. In mast cells, induces the rapid tyrosine phosphorylation of STAT6 and thereby controls mast cell survival and release of cytokines such as IL4.

Subcellular location. Secreted Cytoplasm. Nucleus.

Tissue specificity. Most abundant in placenta and skeletal muscle. It is also detected in the heart, lung, liver and kidney. IL15-S21AA is preferentially expressed in tissues such as testis and thymus.

Induction. By interferon-gamma.

Similarity. Belongs to the IL-15/IL-21 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P40933-1	IL15-S48AA	yes
P40933-2	IL15-S21AA

RefSeq proteins (2): NP_000576, NP_751915 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003443	IL-15/IL-21_fam	Family
IPR009079	4_helix_cytokine-like_core	Homologous_superfamily
IPR020439	IL-15	Family
IPR020466	IL-15_mml	Family

Pfam: PF02372

UniProt features (16 total): helix 6, strand 2, disulfide bond 2, signal peptide 1, propeptide 1, chain 1, glycosylation site 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
2Z3Q	X-RAY DIFFRACTION	1.85
2Z3R	X-RAY DIFFRACTION	2
4GS7	X-RAY DIFFRACTION	2.35
2XQB	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P40933-F1	84.73	0.59

Antibody-complex structures (SAbDab): 1 — 2XQB

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 83–133, 90–136

Glycosylation sites (1): 127

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8983432	Interleukin-15 signaling

MSigDB gene sets: 452 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_CELL_ACTIVATION, REACTOME_INTERLEUKIN_2_FAMILY_SIGNALING, MODULE_92, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, MULLIGHAN_NPM1_SIGNATURE_3_UP, WALLACE_PROSTATE_CANCER_RACE_UP, GOBP_NATURAL_KILLER_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, GOBP_REGULATION_OF_PHOSPHORYLATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, GOBP_RESPONSE_TO_PEPTIDE

GO Biological Process (27): natural killer cell differentiation (GO:0001779), natural killer cell proliferation (GO:0001787), positive regulation of cytokine production (GO:0001819), NK T cell proliferation (GO:0001866), immune response (GO:0006955), signal transduction (GO:0007165), tyrosine phosphorylation of STAT protein (GO:0007260), cell-cell signaling (GO:0007267), positive regulation of cell population proliferation (GO:0008284), macrophage differentiation (GO:0030225), positive regulation of interleukin-17 production (GO:0032740), positive regulation of natural killer cell proliferation (GO:0032819), positive regulation of natural killer cell differentiation (GO:0032825), positive regulation of tissue remodeling (GO:0034105), interleukin-15-mediated signaling pathway (GO:0035723), positive regulation of T cell proliferation (GO:0042102), neutrophil activation (GO:0042119), extrathymic T cell selection (GO:0045062), regulation of T cell differentiation (GO:0045580), cell maturation (GO:0048469), lymph node development (GO:0048535), regulation of defense response to virus by host (GO:0050691), positive regulation of inflammatory response (GO:0050729), positive regulation of peptidyl-tyrosine phosphorylation (GO:0050731), positive regulation of phagocytosis (GO:0050766), positive regulation of immune response (GO:0050778), negative regulation of cold-induced thermogenesis (GO:0120163)

GO Molecular Function (3): cytokine activity (GO:0005125), cytokine receptor binding (GO:0005126), protein binding (GO:0005515)

GO Cellular Component (9): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), endosome (GO:0005768), Golgi apparatus (GO:0005794), cytosol (GO:0005829), nuclear speck (GO:0016607), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Interleukin-2 family signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
natural killer cell activation	2
positive regulation of multicellular organismal process	2
cell communication	2
signaling	2
positive regulation of natural killer cell activation	2
positive regulation of lymphocyte proliferation	2
endomembrane system	2
cytoplasm	2
intracellular membrane-bounded organelle	2
lymphocyte differentiation	1
lymphocyte proliferation	1
cytokine production	1
regulation of cytokine production	1
positive regulation of gene expression	1
alpha-beta T cell proliferation	1
NK T cell activation	1
immune system process	1
response to stimulus	1
cellular process	1
regulation of cellular process	1
cellular response to stimulus	1
cell surface receptor signaling pathway via JAK-STAT	1
peptidyl-tyrosine phosphorylation	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
myeloid leukocyte differentiation	1
mononuclear cell differentiation	1
positive regulation of cytokine production	1
interleukin-17 production	1
regulation of interleukin-17 production	1
natural killer cell proliferation	1
regulation of natural killer cell proliferation	1
natural killer cell differentiation	1
regulation of natural killer cell differentiation	1
positive regulation of lymphocyte differentiation	1
regulation of tissue remodeling	1
tissue remodeling	1
cytokine-mediated signaling pathway	1

Protein interactions and networks

STRING

3104 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL15	IL15RA	Q13261	999
IL15	IL2RG	P31785	998
IL15	IL2RB	P14784	996
IL15	JAK3	P52333	993
IL15	IL9	P15248	977
IL15	IL2RA	P01589	972
IL15	IL7	P13232	966
IL15	IL2	P01585	958
IL15	IL7R	P16871	937
IL15	IFNG	P01579	935
IL15	CD8A	P01732	934
IL15	KLRK1	P26718	917
IL15	IL4	P05112	916
IL15	FCGR3B	O75015	916
IL15	FCGR3A	P08637	916

IntAct

13 interactions, top by confidence:

A	B	Type	Score
IL15	IL2RB	psi-mi:“MI:0915”(physical association)	0.660
IL15	IL2RB	psi-mi:“MI:0407”(direct interaction)	0.660
IL2RB	IL15	psi-mi:“MI:0915”(physical association)	0.660
IL15	IL15RA	psi-mi:“MI:0915”(physical association)	0.660
IL15RA	IL15	psi-mi:“MI:0915”(physical association)	0.660
IL15RA	IL2RB	psi-mi:“MI:0915”(physical association)	0.590
STAT5B	IL15	psi-mi:“MI:0915”(physical association)	0.370
TRAF3	IL15	psi-mi:“MI:0915”(physical association)	0.370
IL15	POLR1H	psi-mi:“MI:0915”(physical association)	0.370
IL15	GAPDHS	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): LRIG1 (Affinity Capture-MS), COL14A1 (Affinity Capture-MS), GAPDHS (Affinity Capture-MS), S100P (Reconstituted Complex), S100A6 (Reconstituted Complex), APP (Reconstituted Complex), ZNRD1 (Two-hybrid), STAT5B (Two-hybrid), TRAF3 (Two-hybrid)

ESM2 similar proteins: A0A1B0GTR0, A0A1B0GVN3, A6H7F9, A6NFE2, A7TZG1, A7TZG3, A7XV04, A7XV14, B0ZE70, B1B212, B2RTN2, B3F0J0, D2HQI1, O97687, P01586, P06740, P16745, P22794, P40221, P40933, P48092, P48346, P97604, Q01151, Q28028, Q29RT9, Q3TB92, Q3Y5G8, Q4GZL1, Q4U0U2, Q5BK38, Q5DT36, Q5DT37, Q5RBQ2, Q5RFR2, Q5UKY4, Q5WQV8, Q62875, Q68D85, Q75SZ9

Diamond homologs: B0ZE70, B3F0J0, O97687, P40221, P40933, P48092, P48346, P97604, Q28028, Q3Y5G8, Q4GZL1, Q4U0U2, Q5WQV8, Q75SZ9, Q95253, Q9XSJ6

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
IL15	up-regulates	IL2RG	binding
IL15	up-regulates	IL15RA	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

27 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	14
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1696 predictions. Top by Δscore:

Variant	Effect	Δscore
4:141636746:G:GT	donor_gain	1.0000
4:141656184:A:AG	acceptor_gain	1.0000
4:141656185:G:GG	acceptor_gain	1.0000
4:141656304:TCGT:T	donor_gain	1.0000
4:141656306:GT:G	donor_gain	1.0000
4:141656307:TG:T	donor_loss	1.0000
4:141656308:G:GA	donor_loss	1.0000
4:141656308:G:GG	donor_gain	1.0000
4:141656309:TAA:T	donor_loss	1.0000
4:141727938:A:AG	acceptor_gain	1.0000
4:141727939:G:GG	acceptor_gain	1.0000
4:141727983:ACG:A	donor_loss	1.0000
4:141727984:CGT:C	donor_loss	1.0000
4:141727985:G:GG	donor_gain	1.0000
4:141727985:G:T	donor_loss	1.0000
4:141727986:T:A	donor_loss	1.0000
4:141729842:TTTA:T	acceptor_loss	1.0000
4:141729844:TA:T	acceptor_loss	1.0000
4:141729845:A:AG	acceptor_gain	1.0000
4:141729845:A:C	acceptor_loss	1.0000
4:141729846:G:GA	acceptor_gain	1.0000
4:141729846:GCC:G	acceptor_gain	1.0000
4:141729846:GCCC:G	acceptor_gain	1.0000
4:141729846:GCCCA:G	acceptor_gain	1.0000
4:141729982:GGG:G	donor_gain	1.0000
4:141729983:GG:G	donor_gain	1.0000
4:141729983:GGG:G	donor_gain	1.0000
4:141729984:GG:G	donor_gain	1.0000
4:141729985:G:GG	donor_gain	1.0000
4:141732737:GAAT:G	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000087987 (4:141679672 T>C), RS1000098890 (4:141697142 G>A), RS1000114336 (4:141649693 A>G), RS1000117832 (4:141662195 T>C), RS1000125541 (4:141727496 A>G), RS1000131873 (4:141688460 G>C), RS1000145665 (4:141646509 T>C), RS1000159600 (4:141655593 G>A), RS1000224005 (4:141696531 T>C), RS1000250135 (4:141642974 G>C), RS1000255053 (4:141675634 G>A), RS1000269283 (4:141703876 G>A,C), RS1000310244 (4:141652818 G>T), RS1000374653 (4:141709825 G>A,T), RS1000395410 (4:141668323 T>A)

Disease associations

OMIM: gene MIM:600554 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST000323_4	Response to treatment for acute lymphoblastic leukemia	9.000000e-07
GCST005566_11	Insomnia	9.000000e-07
GCST008270_1	Post-traumatic stress disorder symptoms in trauma-exposed soldiers	3.000000e-08
GCST010725_4	Malaria	4.000000e-10
GCST010725_84	Malaria	7.000000e-11
GCST010725_89	Malaria	7.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008483	response to trauma exposure
EFO:0008535	post-traumatic stress disorder symptom measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3712954 (SINGLE PROTEIN), CHEMBL4106128 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

2 measured of 2 human assays (2 total across all organisms); most potent 2 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL4067098	KD	16000 nM
CHEMBL4066088	KD	78000 nM

ChEMBL bioactivities

40 potent at pChembl≥5 of 76 total, top 40 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.30	IC50	50	nM	CHEMBL4857666
6.72	IC50	190	nM	CHEMBL4103753
6.55	IC50	280	nM	CHEMBL4846844
6.15	IC50	710	nM	CHEMBL4851186
6.10	IC50	800	nM	CHEMBL4079889
6.10	IC50	800	nM	CHEMBL4101389
6.10	IC50	800	nM	CHEMBL4085913
5.96	IC50	1100	nM	CHEMBL4066271
5.96	IC50	1100	nM	CHEMBL4069144
5.89	IC50	1300	nM	CHEMBL4093847
5.89	IC50	1300	nM	CHEMBL4066448
5.89	Kd	1300	nM	CHEMBL4103753
5.85	IC50	1400	nM	CHEMBL4063508
5.82	IC50	1500	nM	CHEMBL4085144
5.80	IC50	1600	nM	CHEMBL4096400
5.80	IC50	1600	nM	CHEMBL4066088
5.75	IC50	1800	nM	CHEMBL4087773
5.72	IC50	1900	nM	CHEMBL4103753
5.72	IC50	1900	nM	CHEMBL4093663
5.64	IC50	2300	nM	CHEMBL4079593
5.64	IC50	2300	nM	CHEMBL4074888
5.64	IC50	2300	nM	CHEMBL4101575
5.62	Kd	2400	nM	CHEMBL4846844
5.48	IC50	3300	nM	CHEMBL4065977
5.46	Kd	3500	nM	CHEMBL4857666
5.42	IC50	3800	nM	CHEMBL4067098
5.41	IC50	3900	nM	CHEMBL4088685
5.41	Kd	3900	nM	CHEMBL4852416
5.39	IC50	4100	nM	CHEMBL4079499
5.38	IC50	4200	nM	CHEMBL4864820
5.35	IC50	4500	nM	CHEMBL4102828
5.32	IC50	4800	nM	CHEMBL4070160
5.23	Kd	5900	nM	CHEMBL4851186
5.18	IC50	6600	nM	CHEMBL4096087
5.14	IC50	7300	nM	CHEMBL4083909
5.12	IC50	7600	nM	CHEMBL4082181
5.11	Kd	7800	nM	CHEMBL4847472
5.06	IC50	8700	nM	CHEMBL4088362
5.02	IC50	9500	nM	CHEMBL4864898
5.01	IC50	9800	nM	CHEMBL4060991

PubChem BioAssay actives

40 with measured affinity, of 159 total; 35 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-(4-benzoylphenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1763549: Inhibition of IL-15-induced STAT3 phosphorylation in human NK92 cells incubated for 30 mins followed by IL-15 stimulation and measured after 1 hr by alphascreen assay	ic50	0.0500	uM
N-(2,4-dichlorophenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1763549: Inhibition of IL-15-induced STAT3 phosphorylation in human NK92 cells incubated for 30 mins followed by IL-15 stimulation and measured after 1 hr by alphascreen assay	ic50	0.1900	uM
N-(2,4-dichlorophenyl)-8-[[5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]sulfanyl]octanamide	1763549: Inhibition of IL-15-induced STAT3 phosphorylation in human NK92 cells incubated for 30 mins followed by IL-15 stimulation and measured after 1 hr by alphascreen assay	ic50	0.2800	uM
N-(2,4-dichlorophenyl)-8-[[5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-4-(3-oxopropyl)-1,2,4-triazol-3-yl]sulfanyl]octanamide	1763549: Inhibition of IL-15-induced STAT3 phosphorylation in human NK92 cells incubated for 30 mins followed by IL-15 stimulation and measured after 1 hr by alphascreen assay	ic50	0.7100	uM
ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	0.8000	uM
(2,4-dichlorophenyl) 8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoate	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	0.8000	uM
N-(4-chlorophenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	0.8000	uM
N-(2,4-dimethoxyphenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.1000	uM
8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]-N-(4-propan-2-yloxyphenyl)octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.1000	uM
N-(2-hydroxy-4-methoxyphenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.3000	uM
N-(4-iodophenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.3000	uM
N-(2,4-dibromophenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfonyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.4000	uM
N-(2,4-dibromophenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.5000	uM
N-(1-adamantyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.6000	uM
8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]-N-(4-propoxyphenyl)octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.6000	uM
N-(4-azidophenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.8000	uM
8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]-N-naphthalen-1-yloctanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	1.9000	uM
N-(2-chloro-4-methylphenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	2.3000	uM
N-(2,4-difluorophenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	2.3000	uM
N-(2,4-dichlorophenyl)-10-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]decanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	2.3000	uM
N-(2,4-dichlorophenyl)-11-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]undecanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	3.3000	uM
N-(1-adamantyl)-11-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]undecanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	3.8000	uM
N-(4-methoxyphenyl)-8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	3.9000	uM
N-(2,4-dichlorophenyl)-8-[[5-[[3-(3-hydroxypropyl)-4-oxophthalazin-1-yl]methyl]-4-methyl-1,2,4-triazol-3-yl]sulfanyl]octanamide	1763551: Binding affinity to recombinant human IL-15 assessed as dissociation constant by SPR analysis	kd	3.9000	uM
N-(2,4-dichlorophenyl)-6-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]hexanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	4.1000	uM
N-(2,4-dichlorophenyl)-2-[[5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-4-(3-oxopropyl)-1,2,4-triazol-3-yl]sulfanyl]acetamide	1763549: Inhibition of IL-15-induced STAT3 phosphorylation in human NK92 cells incubated for 30 mins followed by IL-15 stimulation and measured after 1 hr by alphascreen assay	ic50	4.2000	uM
N-(2,4-dichlorophenyl)-2-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]acetamide	1763549: Inhibition of IL-15-induced STAT3 phosphorylation in human NK92 cells incubated for 30 mins followed by IL-15 stimulation and measured after 1 hr by alphascreen assay	ic50	4.5000	uM
8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]-N-[4-(2-methylpropoxy)phenyl]octanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	4.8000	uM
11-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]-N-naphthalen-1-ylundecanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	6.6000	uM
N-(2,4-dichlorophenyl)-16-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]hexadecanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	7.3000	uM
4-[(5-decylsulfanyl-4-methyl-1,2,4-triazol-3-yl)methyl]-2-methylphthalazin-1-one	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	7.6000	uM
N-(2,4-dichlorophenyl)-8-[[4-methyl-5-[[4-oxo-3-(3-oxopropyl)phthalazin-1-yl]methyl]-1,2,4-triazol-3-yl]sulfanyl]octanamide	1763551: Binding affinity to recombinant human IL-15 assessed as dissociation constant by SPR analysis	kd	7.8000	uM
(2,4-dichlorophenyl) 11-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]undecanoate	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	8.7000	uM
3-[3-[8-(2,4-dichloroanilino)-8-oxooctyl]sulfanyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-4-yl]propanoic acid	1763549: Inhibition of IL-15-induced STAT3 phosphorylation in human NK92 cells incubated for 30 mins followed by IL-15 stimulation and measured after 1 hr by alphascreen assay	ic50	9.5000	uM
N-(2,4-dichlorophenyl)-4-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]butanamide	1446037: Inhibition of human IL-15Ralpha-sushi domain/human IL-15-induced mouse 32D-beta cell proliferation preincubated for 30 mins with protein followed by cell addition measured after 2.5 days by Alamar blue reduction assay	ic50	9.8000	uM

CTD chemical–gene interactions

85 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Particulate Matter	decreases expression, increases abundance, increases expression	5
Estradiol	increases expression, decreases expression, affects expression, affects cotreatment	4
Lipopolysaccharides	decreases reaction, increases expression, increases secretion, affects cotreatment	4
Arsenic Trioxide	decreases expression, increases expression	3
Progesterone	affects cotreatment, increases expression	3
Valproic Acid	increases expression	3
bisphenol A	decreases expression, decreases methylation	2
trichostatin A	decreases reaction, increases expression	2
(+)-JQ1 compound	decreases reaction, increases expression, decreases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Dexamethasone	decreases reaction, increases expression	2
Nickel	increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cyclosporine	increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases reaction, increases expression	1
coagulin-L	decreases reaction, increases expression	1
bisphenol F	decreases methylation	1
TL8-506	affects cotreatment, increases expression	1
deoxynivalenol	increases expression	1
tributyltin	affects cotreatment, decreases secretion	1
quercitrin	decreases expression	1
trimellitic anhydride	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
nickel chloride	affects cotreatment, increases secretion	1
3,4,5,3’,4’-pentachlorobiphenyl	increases expression	1
nickel sulfate	affects expression	1
hydroquinone	decreases secretion	1
heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine	affects cotreatment, increases expression	1

ChEMBL screening assays

9 unique, capped per target: 9 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4013730	Binding	Binding affinity to recombinant human IL-15 by SPR assay	Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization. — J Med Chem

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8I7	Abcam HCT 116 IL15 KO	Cancer cell line	Male
CVCL_B9KG	Abcam A-549 IL15 KO	Cancer cell line	Male
CVCL_C7IL	K562-mb15	Cancer cell line	Female
CVCL_C7IM	K562-mb15-41BBL	Cancer cell line	Female
CVCL_XD94	THP-1/IL15	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.